These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 16620363)

  • 1. Sitaxsentan: an endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension.
    O'Callaghan DS; Gaine SP
    Int J Clin Pract; 2006 Apr; 60(4):475-81. PubMed ID: 16620363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sitaxsentan, a selective endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension.
    Horn EM; Widlitz AC; Barst RJ
    Expert Opin Investig Drugs; 2004 Nov; 13(11):1483-92. PubMed ID: 15500395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of sitaxsentan sodium in patients with pulmonary arterial hypertension.
    Waxman AB
    Vasc Health Risk Manag; 2007; 3(1):151-7. PubMed ID: 17583185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sitaxsentan: a novel endothelin-A receptor antagonist for pulmonary arterial hypertension.
    Widlitz AC; Barst RJ; Horn EM
    Expert Rev Cardiovasc Ther; 2005 Nov; 3(6):985-91. PubMed ID: 16292989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.
    Barst RJ; Langleben D; Badesch D; Frost A; Lawrence EC; Shapiro S; Naeije R; Galie N;
    J Am Coll Cardiol; 2006 May; 47(10):2049-56. PubMed ID: 16697324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STRIDE 1: effects of the selective ET(A) receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials.
    Langleben D; Brock T; Dixon R; Barst R;
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S80-4. PubMed ID: 15838366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease.
    Girgis RE; Frost AE; Hill NS; Horn EM; Langleben D; McLaughlin VV; Oudiz RJ; Robbins IM; Seibold JR; Shapiro S; Tapson VF; Barst RJ
    Ann Rheum Dis; 2007 Nov; 66(11):1467-72. PubMed ID: 17472992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension.
    Barst RJ
    Expert Opin Pharmacother; 2007 Jan; 8(1):95-109. PubMed ID: 17163810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The endothelin system in pulmonary arterial hypertension.
    Galié N; Manes A; Branzi A
    Cardiovasc Res; 2004 Feb; 61(2):227-37. PubMed ID: 14736539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sitaxsentan in the management of pulmonary arterial hypertension.
    Benedict NJ
    Am J Health Syst Pharm; 2007 Feb; 64(4):363-8. PubMed ID: 17299175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sitaxsentan sodium for pulmonary hypertension.
    MacIntyre IM; Dhaun N; Goddard J; Webb DJ
    Drugs Today (Barc); 2008 Aug; 44(8):585-600. PubMed ID: 18846270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of STRIDE-2 and STRIDE-2X: the case for selective endothelin receptor blockade.
    Langleben D; Cacoub P
    Eur J Clin Invest; 2009 Jun; 39 Suppl 2():27-31. PubMed ID: 19335744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study.
    Barst RJ; Rich S; Widlitz A; Horn EM; McLaughlin V; McFarlin J
    Chest; 2002 Jun; 121(6):1860-8. PubMed ID: 12065350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelin receptor antagonists in pulmonary arterial hypertension.
    Dupuis J; Hoeper MM
    Eur Respir J; 2008 Feb; 31(2):407-15. PubMed ID: 18238950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sitaxsentan for treatment of pulmonary hypertension.
    Wittbrodt ET; Abubakar A
    Ann Pharmacother; 2007 Jan; 41(1):100-5. PubMed ID: 17164394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension.
    Sandoval J; Torbicki A; Souza R; Ramírez A; Kurzyna M; Jardim C; Jerjes-Sánchez Díaz C; Teal SA; Hwang LJ; Pulido T;
    Pulm Pharmacol Ther; 2012 Feb; 25(1):33-9. PubMed ID: 22079088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual ET(A)/ET(B) vs. selective ET(A) endothelin receptor antagonism in patients with pulmonary hypertension.
    Opitz CF; Ewert R
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():1-9. PubMed ID: 16919004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study.
    Langleben D; Hirsch AM; Shalit E; Lesenko L; Barst RJ
    Chest; 2004 Oct; 126(4):1377-81. PubMed ID: 15486408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelin receptor antagonism in pulmonary arterial hypertension--a role for selective ET(A) inhibition?
    Jacobs A; Preston IR; Gomberg-Maitland M
    Curr Med Res Opin; 2006 Dec; 22(12):2567-74. PubMed ID: 17166339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist.
    Tilton RG; Munsch CL; Sherwood SJ; Chen SJ; Chen YF; Wu C; Block N; Dixon RA; Brock TA
    Pulm Pharmacol Ther; 2000; 13(2):87-97. PubMed ID: 10799286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.